Polycystic ovary syndrome (PCOS) is often associated with obesity, insulin resistance, irregular menstrual periods and pelvic pain. Treatment involves hormonal methods for regulation of menstrual cycle, lifestyle changes and metformin for improving insulin resistance and weight. The aim of our study was to compare changes in body mass index (BMI) of adolescent female with PCOS treated with metformin as compared to lifestyle modification only. Participants: Adolescent and young adult females aged I0-25 years diagnosed with PCOS seen for at least two visits for at least one year on the same treatment. Based on treatment plan, participants were categorized as metformin (metformin + lifestyle changes; metformin + oral contraceptive pills + lifestyle changes) versus control group (oral contraceptive pills + lifestyle changes; lifestyle changes only). Results: Of the 464 charts reviewed, 134 participants met the inclusion criteria. The average time period between the initial and follow up visit on same treatment plan was two years (Range 1-8 years). The average age of patients at baseline (initial visit) and follow up was 15.3 and 17.7 years, respectively. The majority of participants were overweight or obese at baseline and follow up. There was not a significant difference between the metformin and control group in the number of patients who stayed in the same BMI category, went up in a BMI category, or went down in a BMI category from baseline to follow up (x" - 1.93, p - 0.38). Conclusion: Treatment with metformin did not relate to changes in BMI classification over a year or more.
Briggs, Alissa; Sadhir, Mandakini; Todd, Maya; and Omar, Hatim A., "Effect of Metformin on Body Mass Index in Adolescent Females with Polycystic Ovary Syndrome" (2016). Pediatrics Faculty Publications. 242.